United Therapeutics Stock Z Score
UTHR Stock | USD 262.40 4.27 1.65% |
United | Z Score |
United Therapeutics Company Z Score Analysis
United Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
United Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for United Therapeutics is extremely important. It helps to project a fair market value of United Stock properly, considering its historical fundamentals such as Z Score. Since United Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of United Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of United Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
As per the company's disclosures, United Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
United Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
United Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in United Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of United Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing United Therapeutics' value.Shares | Aqr Capital Management Llc | 2023-12-31 | 551.8 K | Nuveen Asset Management, Llc | 2023-12-31 | 491.5 K | Farallon Capital Management, L.l.c. | 2023-12-31 | 476 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 459.7 K | Norges Bank | 2023-12-31 | 457.1 K | Fuller & Thaler Asset Management Inc | 2023-12-31 | 431.1 K | Palo Alto Investors, Llc | 2023-12-31 | 395.8 K | Orbimed Advisors, Llc | 2023-12-31 | 386.1 K | Lsv Asset Management | 2023-12-31 | 377.4 K | Blackrock Inc | 2023-12-31 | 5.3 M | Vanguard Group Inc | 2023-12-31 | 4.7 M |
United Fundamentals
Return On Equity | 0.2 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.42 % | ||||
Operating Margin | 0.53 % | ||||
Current Valuation | 9.53 B | ||||
Shares Outstanding | 44.37 M | ||||
Shares Owned By Insiders | 1.84 % | ||||
Shares Owned By Institutions | 98.16 % | ||||
Number Of Shares Shorted | 4.32 M | ||||
Price To Earning | 23.49 X | ||||
Price To Book | 1.83 X | ||||
Price To Sales | 4.70 X | ||||
Revenue | 2.33 B | ||||
Gross Profit | 1.78 B | ||||
EBITDA | 1.39 B | ||||
Net Income | 984.8 M | ||||
Cash And Equivalents | 2.26 B | ||||
Cash Per Share | 49.55 X | ||||
Total Debt | 700 M | ||||
Debt To Equity | 0.18 % | ||||
Current Ratio | 8.10 X | ||||
Book Value Per Share | 120.76 X | ||||
Cash Flow From Operations | 978 M | ||||
Short Ratio | 7.97 X | ||||
Earnings Per Share | 21.12 X | ||||
Price To Earnings To Growth | 7.80 X | ||||
Target Price | 300.95 | ||||
Number Of Employees | 1.17 K | ||||
Beta | 0.55 | ||||
Market Capitalization | 11.64 B | ||||
Total Asset | 7.17 B | ||||
Retained Earnings | 6.03 B | ||||
Working Capital | 2.75 B | ||||
Current Asset | 1.28 B | ||||
Current Liabilities | 440.82 M | ||||
Net Asset | 7.17 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
United Therapeutics Investors Sentiment
The influence of United Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in United. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average United Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on United Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards United Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, United Therapeutics' short interest history, or implied volatility extrapolated from United Therapeutics options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out United Therapeutics Piotroski F Score and United Therapeutics Valuation analysis. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.27 | Earnings Share 21.12 | Revenue Per Share 53.184 | Quarterly Revenue Growth 0.337 | Return On Assets 0.1225 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.